Agilent Technologies, BioTrove to Streamline Drug Discovery Using High-Throughput Mass Spectrometry
News Oct 28, 2008
This solution will combine technology leader BioTrove’s RapidFire Mass Spectrometry sample preparation system with Agilent’s rugged, accurate mass spectrometers. The reseller agreement expands on an established strategic relationship between Agilent and BioTrove, furthering both companies’ ability to enhance customer workflows.
BioTrove will provide an integrated solution for drug discovery using mass spectrometry analysis, affording customers access to a single system. BioTrove’s RapidFire system – comprised of robotics and microfluidic handling for sample preparation and advanced software – combined with Agilent’s Triple Quadrupole and Time-of-Flight mass spectrometry instruments create a high-throughput advanced workflow solution. The agreement includes Agilent atmospheric pressure ionization sources with the mass spectrometers, which generate reliable quantitative and qualitative results via highly sensitive and selective mass analysis, based on the molecular composition of the target compounds.
RapidFire mass spectrometry greatly decreases the bottleneck that occurs during high-throughput screening of candidate drug compounds by enabling automated sample preparation, at a rate of approximately six to eight seconds per sample, followed by seamless integration with the mass spectrometer. Currently used by 11 of the world’s largest 15 pharmaceutical companies, the RapidFire system is one of the fastest and most innovative drug discovery solutions on the market.
“Agilent has emerged as a leader in high-speed LC/MS systems and this partnership offers customers a truly high-throughput assay system and will enable unique, label-free assays that were previously virtually impossible,” said Gus Salem, general manager for Agilent’s LC/MS business. “Agilent is pleased to partner with BioTrove’s RapidFire system, the fastest sample-introduction technology on the market for LC/MS, to offer customers greater speed, throughput and enhanced productivity.”
“Our expanded collaboration enables our biopharmaceutical customers to unleash their research creativity while we focus on enhanced screening applications,” said Al Luderer, Ph.D., president and CEO, BioTrove.
“As part of this complete solution, BioTrove will offer the RapidFire system and the mass spectrometer as well as provide support for the integrated system. The seamless end-to-end solution is now available globally via collaboration between Agilent and BioTrove.”
BioTrove will offer complete systems comprised of its RapidFire system combined with a broad offering of Agilent LC/MS systems including but not limited to: Agilent’s popular 6410 Triple Quadrupole LC/MS system, its new 6460 Triple Quadrupole LC/MS system with Agilent Jet Stream technology and industry leading sensitivity, or its 6220 Accurate Mass Time-of-Flight LC/MS system. As Agilent continues to innovate in LC/MS, new systems with even greater sensitivity, mass accuracy and speed will become available.
Test For Designer Drugs Could Help Treat Overdose PatientsNews
Medical professionals are scrambling to meet the growing demand for emergency room treatment, but they’re hampered by the lack of a quick and easy test to screen patients for “designer” drugs. Chemists have now developed such a test and are refining it with the hope that hospitals could eventually use it to choose the appropriate treatment.READ MORE
Comet "Chury's" Late BirthNews
Comets which consist of two parts, like Chury, can form after a catastrophic collision of larger bodies. Such collisions may have taken place in a later phase of our solar system, which suggests that Chury can be much younger than previously assumed. This is shown through computer simulations.READ MORE
Comments | 0 ADD COMMENT
11th International Conference and Exhibition on Metabolomics & Systems Biology
May 17 - May 19, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018